First-pass extracted concept

base editing for cardiovascular disease

Candidate: concept label1 source documents3 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

The abstract frames base editing as part of the editing toolkit being advanced for cardiovascular disease applications.

Source 1DOI PubMed

Resources required

Its use depends on delivery vectors or targeted delivery systems and the associated editing enzymes.

Source 1DOI PubMed

What problem it solves

It contributes to expanding the range of feasible cardiovascular genomic therapies.

Source 1DOI PubMed

What it does not solve

The abstract does not show that base editing alone resolves delivery, immunogenicity, or toxicity barriers.

Source 1DOI PubMed

Alternatives

The review discusses gene editing more broadly and mentions next-generation editors and targeted delivery systems as related approaches.

Source 1DOI PubMed

Evidence Snippets

successful clinical translation of gene and base editing for CVD continues to hinge on two central challenges: efficient and precise delivery and mitigation of immunogenicity and toxicity

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1scope expansionsupports2026Source 1DOI PubMed

Next-generation editors and targeted delivery systems have expanded the scope of feasible cardiovascular applications, but biological barriers still limit translation to well tolerated durable one-time genomic therapies.

Claim 2technical barriersupports2026Source 1DOI PubMed

Emerging editing technologies aim to overcome limited vector cargo capacity, PAM incompatibility, chromatin accessibility, suboptimal editing efficiency, and off-target activity.

Claim 3translation constraintsupports2026Source 1DOI PubMed

Successful clinical translation of gene and base editing for cardiovascular disease depends on efficient and precise delivery and on mitigating immunogenicity and toxicity from both delivery vectors and gene-editing enzymes.